Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768274 | 0.89 | PREP (0.42) | HTTKDM4EHSD17B10GAATP53 | |
| SCHEMBL3600800 | 0.83 | HSD17B10 (0.55) | HTTKDM4EHSD17B10GAATP53 | |
| SCHEMBL6768867 | 0.80 | CYP3A4 (0.38) | PREPCELA1BACE1CYP3A4 | |
| SCHEMBL9008299 | 0.80 | GABRA1 (0.39) | ADRA1ATHRATHRBCYP3A4 | |
| SCHEMBL6764077 | 0.76 | HTT (0.45) | HTTKDM4EHSD17B10GAATP53 | |
| SCHEMBL17935193 | 0.76 | CA1 (0.46) | HTTCYP1A2ADRA2ACYP2D6PKM | |
| SCHEMBL9029438 | 0.74 | BACE1 (0.47) | HTTKDM4ETP53MAPTPKM | |
| SCHEMBL8176820 | 0.74 | FABP3 (0.52) | HTT | |
| SCHEMBL17935202 | 0.74 | CA1 (0.61) | GAAPREPCELA1ALDH1A1THRA | |
| SCHEMBL7921839 | 0.74 | KDM4E (0.57) | HTTKDM4EHSD17B10GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1601641-A4 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1587783-A4 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1601641-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1587783-A2 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | KARO BIO AB (SE) | 2004-09-16 | — | — | US | disclosed |
| US-20040176425-A1 | Cycloalkyl containing anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004066929-A2 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067482-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | TSHR, TRHR, THRA | HTT 3431/4885KDM4E 3009/4885HSD17B10 1740/4885 |
| US-20040176425-A1 | Cycloalkyl containing anilide ligands for the thyroid receptor | TSHR, THRB, TRHR | HTT 3657/4885KDM4E 3573/4885HSD17B10 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.